

# **Hospital Acquired Pneumonia (HAP) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs**

<https://marketpublishers.com/r/H9C6722C3D98EN.html>

Date: October 2019

Pages: 80

Price: US\$ 1,699.00 (Single User License)

ID: H9C6722C3D98EN

## **Abstracts**

Hospital Acquired Pneumonia (HAP) Drug pipeline report- 2020 is an annual R&D review of Hospital Acquired Pneumonia (HAP) pipeline candidates. The report presents the current status of all major Hospital Acquired Pneumonia (HAP) therapeutic compounds. Detailed insights into Hospital Acquired Pneumonia (HAP) pipeline development, current status, companies, drug profiles and Hospital Acquired Pneumonia (HAP) preclinical and clinical trials are included.

### **2020 Hospital Acquired Pneumonia (HAP) Pipeline Market Insights**

Hospital Acquired Pneumonia (HAP) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Hospital Acquired Pneumonia (HAP) therapies, pipeline by phase and others are included.

### **Hospital Acquired Pneumonia (HAP) pipeline Drug profiles-**

Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

### **Hospital Acquired Pneumonia (HAP) Therapeutic Drug candidates**

Both active and inactive Hospital Acquired Pneumonia (HAP) pipeline drug candidates are included in the report

### **Hospital Acquired Pneumonia (HAP) Clinical Trials and preclinical Studies**

Hospital Acquired Pneumonia (HAP) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Hospital Acquired Pneumonia (HAP) pipeline market developments  
Hospital Acquired Pneumonia (HAP) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Hospital Acquired Pneumonia (HAP) pipeline companies in active development  
The report analyzes Hospital Acquired Pneumonia (HAP) pipeline of the below companies-

Aridis Pharmaceuticals Inc, AstraZeneca Plc, Biolytx Pharmaceuticals Corp, Centauri Therapeutics Ltd, Cumberland Pharmaceuticals Inc, Destiny Pharma Ltd, Dong-A Socio Holdings Co Ltd, EnBiotix Inc, Evaxion Biotech ApS, MedImmune LLC, Meiji Seika Pharma Co Ltd, Merck & Co Inc, Motif Bio Plc, Nabriva Therapeutics plc, Peptineo, Polyphor AG, Sealife PHARMA GMBH, Shionogi & Co Ltd, Spero Therapeutics Inc, Tetrphase Pharmaceuticals Inc, TGV Laboratories Inc, Wockhardt Ltd

## Report Coverage

### What to look out for in 2020

Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

### Pipeline Snapshot

Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

### Companies

22 Companies investing in Hospital Acquired Pneumonia (HAP) pipeline from discovery stage to pre-registration phase are included

### Drug profiles

Over 10 details of each Hospital Acquired Pneumonia (HAP) pipeline candidate are included

### Company Profiles

Business overview and contact details of all companies operating in the industry are provided

Market Developments

News, Developments and other recent industry developments are included

## Contents

### **1. HOSPITAL ACQUIRED PNEUMONIA (HAP) PIPELINE MARKET INSIGHTS, 2020**

- 1.1 Hospital Acquired Pneumonia (HAP) Disease Overview
- 1.2 Hospital Acquired Pneumonia (HAP) Drug Pipeline Snapshot, 2020
  - 1.2.1 Hospital Acquired Pneumonia (HAP) Pipeline Drugs by Phase
  - 1.2.2 Hospital Acquired Pneumonia (HAP) Pipeline Drugs by Company
  - 1.2.3 Hospital Acquired Pneumonia (HAP) Pipeline Drugs by Mechanism of Action
  - 1.2.4 Hospital Acquired Pneumonia (HAP) Pipeline Drugs by Route of Administration

### **2. HOSPITAL ACQUIRED PNEUMONIA (HAP) COMPANY WISE PIPELINE DETAILS**

Aridis Pharmaceuticals Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

AstraZeneca Plc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Biolytx Pharmaceuticals Corp Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Centauri Therapeutics Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Cumberland Pharmaceuticals Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Destiny Pharma Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Dong-A Socio Holdings Co Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

EnBiotix Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

Drug Candidate Details

Evaxion Biotech ApS Hospital Acquired Pneumonia (HAP) Pipeline Drugs

Company Profile

- Drug Candidate Details
- MedImmune LLC Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Meiji Seika Pharma Co Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Merck & Co Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Motif Bio Plc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Nabriva Therapeutics plc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Peptineo Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Polyphor AG Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Sealife PHARMA GMBH Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Shionogi & Co Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Spero Therapeutics Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Tetraphase Pharmaceuticals Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- TGV Laboratories Inc Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile
  - Drug Candidate Details
- Wockhardt Ltd Hospital Acquired Pneumonia (HAP) Pipeline Drugs
  - Company Profile

Drug Candidate Details

### **3. HOSPITAL ACQUIRED PNEUMONIA (HAP) DRUG PIPELINE PROFILES**

3.1 Discovery and Preclinical Drug Profiles

3.2 Phase 1 Drug Profiles

3.3 Phase 2 Drug Profiles

3.4 Phase 3 Drug Profiles

### **4. HOSPITAL ACQUIRED PNEUMONIA (HAP) PIPELINE NEWS AND DEVELOPMENTS**

### **5. APPENDIX**

5.1 Primary and Secondary Research Methodology

5.2 Publisher Expertize

5.3 Contacts

## I would like to order

Product name: Hospital Acquired Pneumonia (HAP) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

Product link: <https://marketpublishers.com/r/H9C6722C3D98EN.html>

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H9C6722C3D98EN.html>